Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance

Grimm, Max Joseph ; Respondek, Gesine ; Stamelou, Maria ; Arzberger, Thomas ; Ferguson, Leslie ; Gelpi, Ellen ; Giese, Armin ; Grossman, Murray ; Irwin, David J. and Pantelyat, Alexander , et al. (2020) In Movement Disorders 35(12). p.2301-2313
Abstract

Background: The Movement Disorder Society diagnostic criteria for progressive supranuclear palsy introduced the diagnostic certainty level “suggestive of progressive supranuclear palsy” for clinical conditions with subtle signs, suggestive of the disease. This category aims at the early identification of patients, in whom the diagnosis may be confirmed as the disease evolves. Objective: To assess the diagnostic performance of the defined clinical conditions suggestive of progressive supranuclear palsy in an autopsy-confirmed cohort. Methods: Diagnostic performance of the criteria was analyzed based on retrospective clinical data of 204 autopsy-confirmed patients with progressive supranuclear palsy and 216 patients with other... (More)

Background: The Movement Disorder Society diagnostic criteria for progressive supranuclear palsy introduced the diagnostic certainty level “suggestive of progressive supranuclear palsy” for clinical conditions with subtle signs, suggestive of the disease. This category aims at the early identification of patients, in whom the diagnosis may be confirmed as the disease evolves. Objective: To assess the diagnostic performance of the defined clinical conditions suggestive of progressive supranuclear palsy in an autopsy-confirmed cohort. Methods: Diagnostic performance of the criteria was analyzed based on retrospective clinical data of 204 autopsy-confirmed patients with progressive supranuclear palsy and 216 patients with other neurological diseases. Results: The conditions suggestive of progressive supranuclear palsy strongly increased the sensitivity compared to the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy criteria. Within the first year after symptom onset, 40% of patients with definite progressive supranuclear palsy fulfilled criteria for suggestive of progressive supranuclear palsy. Two-thirds of patients suggestive of progressive supranuclear palsy evolved into probable progressive supranuclear palsy after an average of 3.6 years. Application of the criteria for suggestive of progressive supranuclear palsy reduced the average time to diagnosis from 3.8 to 2.2 years. Conclusions: Clinical conditions suggestive of progressive supranuclear palsy allow earlier identification of patients likely to evolve into clinically possible or probable progressive supranuclear and to have underlying progressive supranuclear palsy pathology. Further work needs to establish the specificity and positive predictive value of this category in real-life clinical settings, and to develop specific biomarkers that enhance their diagnostic accuracy in early disease stages.

(Less)
Please use this url to cite or link to this publication:
@article{d168f356-17eb-4cd8-9d0e-461fe469b2fa,
  abstract     = {{<p>Background: The Movement Disorder Society diagnostic criteria for progressive supranuclear palsy introduced the diagnostic certainty level “suggestive of progressive supranuclear palsy” for clinical conditions with subtle signs, suggestive of the disease. This category aims at the early identification of patients, in whom the diagnosis may be confirmed as the disease evolves. Objective: To assess the diagnostic performance of the defined clinical conditions suggestive of progressive supranuclear palsy in an autopsy-confirmed cohort. Methods: Diagnostic performance of the criteria was analyzed based on retrospective clinical data of 204 autopsy-confirmed patients with progressive supranuclear palsy and 216 patients with other neurological diseases. Results: The conditions suggestive of progressive supranuclear palsy strongly increased the sensitivity compared to the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy criteria. Within the first year after symptom onset, 40% of patients with definite progressive supranuclear palsy fulfilled criteria for suggestive of progressive supranuclear palsy. Two-thirds of patients suggestive of progressive supranuclear palsy evolved into probable progressive supranuclear palsy after an average of 3.6 years. Application of the criteria for suggestive of progressive supranuclear palsy reduced the average time to diagnosis from 3.8 to 2.2 years. Conclusions: Clinical conditions suggestive of progressive supranuclear palsy allow earlier identification of patients likely to evolve into clinically possible or probable progressive supranuclear and to have underlying progressive supranuclear palsy pathology. Further work needs to establish the specificity and positive predictive value of this category in real-life clinical settings, and to develop specific biomarkers that enhance their diagnostic accuracy in early disease stages.</p>}},
  author       = {{Grimm, Max Joseph and Respondek, Gesine and Stamelou, Maria and Arzberger, Thomas and Ferguson, Leslie and Gelpi, Ellen and Giese, Armin and Grossman, Murray and Irwin, David J. and Pantelyat, Alexander and Rajput, Alex and Roeber, Sigrun and van Swieten, John C. and Troakes, Claire and Meissner, Wassilios G. and Nilsson, Christer and Piot, Ines and Compta, Yaroslau and Rowe, James B. and Höglinger, Günter U.}},
  issn         = {{0885-3185}},
  keywords     = {{autopsy; clinical diagnostic criteria; early diagnosis; neuropathology; progressive supranuclear palsy; suggestive}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{2301--2313}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Movement Disorders}},
  title        = {{Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance}},
  url          = {{http://dx.doi.org/10.1002/mds.28263}},
  doi          = {{10.1002/mds.28263}},
  volume       = {{35}},
  year         = {{2020}},
}